Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Carlos Rene Duarte Hernandez"'
Autor:
Anna Offersgaard, Carlos Rene Duarte Hernandez, Shan Feng, Pavel Marichal-Gallardo, Kenn Holmbeck, Anne Finne Pihl, Carlota Fernandez-Antunez, Garazi Peña Alzua, Katrine Top Hartmann, Long V. Pham, Yuyong Zhou, Karen Anbro Gammeltoft, Ulrik Fahnøe, Uffe Vest Schneider, Gabriel Kristian Pedersen, Henrik Elvang Jensen, Jan Pravsgaard Christensen, Santseharay Ramirez, Jens Bukh, Judith Margarete Gottwein
Publikováno v:
iScience, Vol 26, Iss 2, Pp 105949- (2023)
Summary: Vaccines have relieved the public health burden of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and globally inactivated vaccines are most widely used. However, poor vaccination accessibility and waning immunity maintain the
Externí odkaz:
https://doaj.org/article/5be313e70944483e85a0601f5bf5dfe3
Autor:
Karen Anbro Gammeltoft, Yuyong Zhou, Line Abildgaard Ryberg, Long V. Pham, Alekxander Binderup, Carlos Rene Duarte Hernandez, Anna Offersgaard, Ulrik Fahnøe, Günther Herbert Johannes Peters, Santseharay Ramirez, Jens Bukh, Judith Margarete Gottwein
Publikováno v:
Viruses, Vol 15, Iss 9, p 1970 (2023)
Nirmatrelvir, which targets the SARS-CoV-2 main protease (Mpro), is the first-in-line drug for prevention and treatment of severe COVID-19, and additional Mpro inhibitors are in development. However, the risk of resistance development threatens the f
Externí odkaz:
https://doaj.org/article/68742ea5f82c460db78afaf14d9d85da
Autor:
Anna Offersgaard, Carlos Rene Duarte Hernandez, Anne Finne Pihl, Nandini Prabhakar Venkatesan, Henrik Krarup, Xiangliang Lin, Udo Reichl, Jens Bukh, Yvonne Genzel, Judith Margarete Gottwein
Publikováno v:
Vaccines, Vol 10, Iss 2, p 249 (2022)
Hepatitis C virus (HCV) infections pose a major public health burden due to high chronicity rates and associated morbidity and mortality. A vaccine protecting against chronic infection is not available but would be important for global control of HCV
Externí odkaz:
https://doaj.org/article/936ce43852514f91a6740978172983f3
Autor:
Anna Offersgaard, Carlos Rene Duarte Hernandez, Anne Finne Pihl, Rui Costa, Nandini Prabhakar Venkatesan, Xiangliang Lin, Long Van Pham, Shan Feng, Ulrik Fahnøe, Troels Kasper Høyer Scheel, Santseharay Ramirez, Udo Reichl, Jens Bukh, Yvonne Genzel, Judith Margarete Gottwein
Publikováno v:
Vaccines, Vol 9, Iss 7, p 706 (2021)
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has demonstrated the value of pursuing different vaccine strategies. Vaccines based on whole viruses, a widely used vaccine technology, depend on efficient virus production. Th
Externí odkaz:
https://doaj.org/article/9945ef9763434cb3a51ccc4033e41d0d
Autor:
Garazi Pena Alzua, Anne Finne Pihl, Anna Offersgaard, Carlos Rene Duarte Hernandez, Zhe Duan, Shan Feng, Ulrik Fahnøe, Christina Sølund, Nina Weis, Mansun Law, Jannick C Prentoe, Jan Pravsgaard Christensen, Jens Bukh, Judith Margarete Gottwein
Publikováno v:
Alzua, G P, Pihl, A F, Offersgaard, A, Duarte Hernandez, C R, Duan, Z, Feng, S, Fahnøe, U, Sølund, C, Weis, N, Law, M, Prentoe, J C, Christensen, J P, Bukh, J & Gottwein, J M 2023, ' Inactivated genotype 1a, 2a and 3a HCV vaccine candidates induced broadly neutralising antibodies in mice ', Gut, vol. 72, no. 3, pp. 560-572 . https://doi.org/10.1136/gutjnl-2021-326323
ObjectiveA prophylactic vaccine is needed to control the HCV epidemic, with genotypes 1–3 causing >80% of worldwide infections. Vaccine development is hampered by HCV heterogeneity, viral escape including protection of conserved neutralising epitop
Autor:
Yuyong Zhou, Karen Anbro Gammeltoft, Line Abildgaard Ryberg, Long V. Pham, Ulrik Fahnøe, Alekxander Binderup, Carlos Rene Duarte Hernandez, Anna Offersgaard, Carlota Fernandez-Antunez, Günther Herbert Johannes Peters, Santseharay Ramirez, Jens Bukh, Judith Margarete Gottwein
The oral protease inhibitor nirmatrelvir is expected to play a pivotal role for prevention of severe cases of coronavirus disease 2019 (COVID-19). To facilitate monitoring of potentially emerging resistance, we studied severe acute respiratory syndro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::205d0aa6c9f6984173d452cb9eb2afbb
https://doi.org/10.1101/2022.06.06.494921
https://doi.org/10.1101/2022.06.06.494921
Autor:
Yuyong Zhou, Karen Anbro Gammeltoft, Line Abildgaard Ryberg, Long V. Pham, Helena Damtoft Tjørnelund, Alekxander Binderup, Carlos Rene Duarte Hernandez, Carlota Fernandez-Antunez, Anna Offersgaard, Ulrik Fahnøe, Günther Herbert Johannes Peters, Santseharay Ramirez, Jens Bukh, Judith Margarete Gottwein
Publikováno v:
Zhou, Y, Gammeltoft, K A, Ryberg, L A, Pham, L V, Tjørnelund, H D, Binderup, A, Hernandez, C R D, Fernandez-Antunez, C, Offersgaard, A, Fahnøe, U, Peters, G H J, Ramirez, S, Bukh, J & Gottwein, J M 2022, ' Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system ', Science Advances, vol. 8, no. 51, eadd7197 . https://doi.org/10.1126/sciadv.add7197
The oral protease inhibitor nirmatrelvir is of key importance for prevention of severe coronavirus disease 2019 (COVID-19). To facilitate resistance monitoring, we studied severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) escape from nirma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d727551774267d20853f0010a21cfc8
https://orbit.dtu.dk/en/publications/3f6c81f6-93ab-4100-b45b-e62a8282a572
https://orbit.dtu.dk/en/publications/3f6c81f6-93ab-4100-b45b-e62a8282a572
Autor:
Yuyong Zhou, Troels K. H. Scheel, Shan Feng, Jens Bukh, Karen A. Gammeltoft, Santseharay Ramirez, Judith M. Gottwein, Long V. Pham, Anna Offersgaard, Andrea Galli, Rui Costa, Carlos Rene Duarte Hernandez, Ulrik Fahnøe
Publikováno v:
Antimicrobial Agents and Chemotherapy
Gammeltoft, K A, Zhou, Y, Duarte Hernandez, C R, Galli, A, Offersgaard, A, Costa, R, Pham, L V, Fahnøe, U, Feng, S, Scheel, T K H, Ramirez, S, Bukh, J & Gottwein, J M 2021, ' Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 in Vitro ', Antimicrobial Agents and Chemotherapy, vol. 65, no. 9, e02680-20 . https://doi.org/10.1128/AAC.02680-20
Gammeltoft, K A, Zhou, Y, Duarte Hernandez, C R, Galli, A, Offersgaard, A, Costa, R, Pham, L V, Fahnøe, U, Feng, S, Scheel, T K H, Ramirez, S, Bukh, J & Gottwein, J M 2021, ' Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 in Vitro ', Antimicrobial Agents and Chemotherapy, vol. 65, no. 9, e02680-20 . https://doi.org/10.1128/AAC.02680-20
Antivirals targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could improve treatment of COVID-19. We evaluated the efficacy of clinically relevant hepatitis C virus (HCV) NS3 protease inhibitors (PIs) against SARS-CoV-2 and their
Autor:
Rui Costa, Jens Bukh, Shan Feng, Anne Finne Pihl, Troels K. H. Scheel, Udo Reichl, Santseharay Ramirez, Judith M. Gottwein, Long V. Pham, Nandini Prabhakar Venkatesan, Carlos Rene Duarte Hernandez, Ulrik Fahnøe, Yvonne Genzel, Anna Offersgaard, Xiangliang Lin
Publikováno v:
Offersgaard, A, Hernandez, C R D, Pihl, A F, Costa, R, Venkatesan, N P, Lin, X, Van Pham, L, Feng, S, Fahnøe, U, Scheel, T K H, Ramirez, S, Reichl, U, Bukh, J, Genzel, Y & Gottwein, J M 2021, ' Sars-cov-2 production in a scalable high cell density bioreactor ', Vaccines, vol. 9, no. 7, 706 . https://doi.org/10.3390/vaccines9070706
Vaccines
Vaccines, Vol 9, Iss 706, p 706 (2021)
Volume 9
Issue 7
Vaccines
Vaccines, Vol 9, Iss 706, p 706 (2021)
Volume 9
Issue 7
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has demonstrated the value of pursuing different vaccine strategies. Vaccines based on whole viruses, a widely used vaccine technology, depend on efficient virus production. Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7534d467521da9a93a898498a75d5e30
https://curis.ku.dk/ws/files/277234545/vaccines_09_00706_v2.pdf
https://curis.ku.dk/ws/files/277234545/vaccines_09_00706_v2.pdf
Autor:
Offersgaard, Anna F., Carlos Rene Duarte Hernandez, Anne Finne Pihl, Shan Feng, Pavel Marichal-Gallardo, Kenn Holmbeck, Nandini Prabhakar Venkatesan, Xianliang Lin, Carlota Fernandez-Antunez, Garazi Pena Alzua, Rui Costa, Katrine Top Hartmann, Long Pham, Yuyong Zhou, Karen Anbro Gammeltoft, Ulrik Fahnøe, Troels Scheel, Uffe Vest Schneider, Henrik Elvang Jensen, Jan Pravsgaard Christensen, Santseharay Ramirez Almeida, Udo Reichl, Yvonne Genzel, Jens Bukh, Judith Gottwein
Publikováno v:
University of Copenhagen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::1ebc6765b2c9a5fc2f2f6fd463d8adb7
https://curis.ku.dk/portal/en/publications/establishment-of-hightiter-hcv-and-sarscov2-production-in-a-scalable-packedbed-bioreactor-for-inactivated-vaccines-inducing-neutralizing-antibodies-in-animals(076d76e1-a9c5-407f-8c2c-8f9be51482ec).html
https://curis.ku.dk/portal/en/publications/establishment-of-hightiter-hcv-and-sarscov2-production-in-a-scalable-packedbed-bioreactor-for-inactivated-vaccines-inducing-neutralizing-antibodies-in-animals(076d76e1-a9c5-407f-8c2c-8f9be51482ec).html